Cellistic is attending the Hanson Wade 6th iPSC Drug Development Summit in Boston.
Published
Signal category
Presence & Recognition
Quote
“That is the conversation we are looking forward to having in Boston at Hanson Wade's 6th iPSC Drug Development Summit.”
— Cellistic team
Company
Cellistic
iPSC-first CDMO. Manufacturing services & platforms for iPSC-derived cell therapy and regenerative medicine
- Industry
- Biotechnology Research
- Location
- Mont-Saint-Guibert, BE
- Company size
- 83 employees
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale. For more information, visit www.cellistic.com.
Founded 2022